RxDoctor Payments Data

William Salerno, MD

Cardiovascular Disease · Saddle Brook, NJNPI 1972683902

Payments from drug & device makers

$965in general payments, 2019–2025

Across 15 payments — averaging $64.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$391
  • AstraZeneca$241
  • Pfizer$151
  • Abbott$142
  • Amgen$31
  • Heartflow, Inc.$9

What the payments were for

  • Food & beverage$95899%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences3$391
AstraZeneca2$241
Pfizer6$151
Abbott1$142
Amgen2$31
Heartflow, Inc.1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$965 in reported general payments places this provider in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$87,142
Medicare patients
697
Services billed
1,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$136,349
Repatha SureclickEvolocumab74$95,068
XareltoRivaroxaban73$79,778
JardianceEmpagliflozin29$49,354
EntrestoSacubitril/Valsartan11$19,460
BrilintaTicagrelor22$16,078
Pitavastatin Calcium27$15,484
Rosuvastatin Calcium422$8,049
Ezetimibe219$7,241
Atorvastatin Calcium387$4,846
Losartan Potassium260$4,514
Nebivolol Hcl41$4,189
Metoprolol Succinate233$4,046
VascepaIcosapent Ethyl12$3,020
Candesartan Cilexetil18$2,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$136,349106 claims
AstraZenecaBrilinta$241$16,07822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Saddle Brook

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →